Literature DB >> 21641518

Use of Chinese medicine by women with breast cancer: a nationwide cross-sectional study in Taiwan.

Yi-Hsien Lin1, Jen-Hwey Chiu.   

Abstract

OBJECTIVES: The National Health Insurance (NHI) provided Western medicine (WM) and Chinese medicine (CM) in Taiwan. This study aims to explore CM use by women with breast cancer under NHI.
METHODS: Using NHI Research Database, a retrospective cross-sectional study was conducted. Women with breast cancer were identified by diagnosis codes. Their claims of CM and WM outpatient services of 2007 were analyzed.
RESULTS: Among 70,012 female breast cancer patients, the prevalence of insurance covered CM was 35.6%. Among all CM users, 4379 (17.5%) patients visited CM for breast cancer. More than half CM users (67.6%) had less than 6 visits and 16.3% users had more than 12 visits. The majority of CM users (87.6%) also used WM ambulatory services. Private clinics (76.7%) provided the most CM services, followed by private hospitals (16.9%). The most frequently used CM therapies were Chinese herbal medicine (80.5%), followed by acupuncture/traumatology manipulative therapies (22.3%). The average cost of CM was US$17.6 per visit and US$119.7 per user annually. CM users were more likely to be younger than 60 years old, employees, with higher income, and not living in Northern Taiwan.
CONCLUSIONS: A significant portion of breast cancer patients used insurance covered CM. Most CM users also used WM. The potential of drug-herb interactions should be concerned.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21641518     DOI: 10.1016/j.ctim.2011.04.001

Source DB:  PubMed          Journal:  Complement Ther Med        ISSN: 0965-2299            Impact factor:   2.446


  19 in total

1.  Use of Chinese medicine among colorectal cancer patients: a nationwide population-based study.

Authors:  Shiang-Jiun Tsai; Ying-Xu Ruan; Ching-Chih Lee; Moon-Sing Lee; Wen-Yen Chiou; Hon-Yi Lin; Feng-Chun Hsu; Yu-Chieh Su; Ta-Wen Hsu; Shih-Kai Hung
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-01-28

Review 2.  Prevalence of the Use of Herbal Medicines among Patients with Cancer: A Systematic Review and Meta-Analysis.

Authors:  John Baptist Asiimwe; Prakash B Nagendrappa; Esther C Atukunda; Mauda M Kamatenesi; Grace Nambozi; Casim U Tolo; Patrick E Ogwang; Ahmed M Sarki
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-17       Impact factor: 2.650

3.  Use of Chinese medicine correlates negatively with the consumption of conventional medicine and medical cost in patients with uterine fibroids: a population-based retrospective cohort study in Taiwan.

Authors:  Shan-Yu Su; Chih-Hsin Muo; Donald E Morisky
Journal:  BMC Complement Altern Med       Date:  2015-04-23       Impact factor: 3.659

4.  Screening to Identify Commonly Used Chinese Herbs That Affect ERBB2 and ESR1 Gene Expression Using the Human Breast Cancer MCF-7 Cell Line.

Authors:  Jen-Hwey Chiu; Chun-Ju Chang; Jing-Chong Wu; Hui-Ju Liu; Che-Sheng Wen; Chung-Hua Hsu; Jiun-Liang Chen; Ling-Ming Tseng; Wei-Shone Chen; Yi-Ming Shyr
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-27       Impact factor: 2.629

5.  Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims.

Authors:  Bih-Ru Wang; Yuh-Lih Chang; Tzeng-Ji Chen; Jen-Hwey Chiu; Jing Chong Wu; Min-Shan Wu; Chia-Lin Chou; Yueh-Ching Chou
Journal:  Patient Prefer Adherence       Date:  2014-05-07       Impact factor: 2.711

6.  A New Herbal Formula, KSG-002, Suppresses Breast Cancer Growth and Metastasis by Targeting NF- κ B-Dependent TNF α Production in Macrophages.

Authors:  Sang-Mi Woo; Youn Kyung Choi; Sung-Gook Cho; Sunju Park; Seong-Gyu Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-30       Impact factor: 2.629

7.  Use of chinese medicine and subsequent surgery in women with uterine fibroid: a retrospective cohort study.

Authors:  Shan-Yu Su; Chih-Hsin Muo; Donald E Morisky
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-16       Impact factor: 2.629

8.  Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients.

Authors:  Huan Tian; Wei Qin; Wenjing Wu; Pi Guo; Yong Lu; Pengxi Liu; Qiang Liu; Fengxi Su
Journal:  Evid Based Complement Alternat Med       Date:  2015-08-12       Impact factor: 2.629

9.  The Malaysian Breast Cancer Survivorship Cohort (MyBCC): a study protocol.

Authors:  Tania Islam; Nirmala Bhoo-Pathy; Tin Tin Su; Hazreen Abdul Majid; Azmi Mohd Nahar; Chong Guan Ng; Maznah Dahlui; Samsinah Hussain; Marie Cantwell; Liam Murray; Nur Aishah Taib
Journal:  BMJ Open       Date:  2015-10-26       Impact factor: 2.692

10.  Hedyotis diffusa Combined with Scutellaria barbata Are the Core Treatment of Chinese Herbal Medicine Used for Breast Cancer Patients: A Population-Based Study.

Authors:  Yuan-Chieh Yeh; Hsing-Yu Chen; Sien-Hung Yang; Yi-Hsien Lin; Jen-Hwey Chiu; Yi-Hsuan Lin; Jiun-Liang Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.